Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBC
NCT07827079Phase 2Completed
- Start
- Oct 2024
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in triple-negative breast cancer (TNBC). Primary endpoint: Pathological Complete Response rate. Started Oct 2024; status: completed.
02
Drugs
tislelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07827079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07827079.